胰岛素样生长因子-1及其结合蛋白与非酒精性脂肪性肝病发生发展的研究进展

doi:10.3969/j.issn.1004-583X.2023.10.014

摘要/Abstract

摘要：

非酒精性脂肪性肝病(NAFLD)是指在没有继发于其他原因(包括过度饮酒、致脂性药物或其他肝脏疾病的原因)的情况下,肝脏脂肪积累>5%的一系列肝脏疾病,包括从单纯的脂肪变性到脂肪性肝炎,再到晚期纤维化、肝硬化,最终是肝细胞癌(HCC)的一系列变化。近期,研究发现,胰岛素样生长因子-1及其结合蛋白(IGFBP)与NAFLD的发生进展有关。IGFBP通过各种基因或细胞途径参与糖脂代谢,增强或减弱肝细胞的氧化应激、炎症、脂肪β氧化等参与NAFLD的发病过程。本文就NAFLD的流行病学、IGFBP对NAFLD发生发展的作用机制进行综述。

关键词: 非酒精性脂肪性肝病, 胰岛素样生长因子-1, 胰岛素样生长因子结合蛋白质类, 肝纤维化

中图分类号:

R575.5

熊璐, 郭莲. 胰岛素样生长因子-1及其结合蛋白与非酒精性脂肪性肝病发生发展的研究进展[J]. 临床荟萃, 2023, 38(10): 935-939.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://huicui.hebmu.edu.cn/CN/10.3969/j.issn.1004-583X.2023.10.014

https://huicui.hebmu.edu.cn/CN/Y2023/V38/I10/935

参考文献 43

[1]	Goyale A, Jain A, Smith C, et al. Assessment of non-alcoholic fatty liver disease (NAFLD) severity with novel serum-based markers: A pilot study[J]. PLoS One, 2021, 16(11):e0260313. doi: 10.1371/journal.pone.0260313 URL
[2]	Farley E, Menter A. Psoriasis: Comorbidities and associations[J]. G Ital Dermatol Venereol, 2011, 146(1):9-15.
[3]	Yin X, Guo X, Liu Z, et al. Advances in the diagnosis and treatment of non-alcoholic fatty liver disease[J]. Int J Mol Sci, 2023, 24(3):2844. doi: 10.3390/ijms24032844 URL
[4]	Karonova T, Belyaeva O, Jude EB, et al. Serum 25(OH)D and adipokines levels in people with abdominal obesity[J]. J Steroid Biochem, 2018, 175:170-176.
[5]	Ono M, Okamoto N, Saibara T. The latest idea in NAFLD/NASH pathogenesis[J]. Clin J Gastroenterol, 2010, 3(6):263-270. doi: 10.1007/s12328-010-0182-9 pmid: 26190482
[6]	Stanley T, Fourman L, Zheng I, et al. Relationship of IGF-1 and IGF-binding proteins to disease severity and glycemia in nonalcoholic fatty liver disease[J]. J Clinl Endocr Metab, 2021, 106(2):e520-e533.
[7]	Dichtel LE, Cordoba-Chacon J, Kineman RD. Growth hormone and insulin-like growth factor 1 regulation of nonalcoholic fatty liver disease[J]. J Clin Endocr Metab, 2022, 107(7):1812-24. doi: 10.1210/clinem/dgac088 URL
[8]	Osganian SA, Subudhi S, Masia R, et al. Expression of IGF-1 receptor and GH receptor in hepatic tissue of patients with nonalcoholic fatty liver disease and nonalcoholic steatohepatitis[J]. Growth Horm Igf Res, 2022, 65:101482. doi: 10.1016/j.ghir.2022.101482 URL
[9]	Sarmento-Cabral A, Del Rio-Moreno M, Vazquez-Borrego MC, et al. GH directly inhibits steatosis and liver injury in a sex-dependent and IGF1-independent manner[J]. J Endocrinol, 2021, 248(1):31-44. doi: 10.1530/JOE-20-0326 pmid: 33112796
[10]	Sumida Y, Yonei Y, Tanaka S, et al. Lower levels of insulin-like growth factor-1 standard deviation score are associated with histological severity of non-alcoholic fatty liver disease[J]. Hepatol Res, 2015, 45(7):771-781. doi: 10.1111/hepr.12408 pmid: 25163357
[11]	杨仁国, 贺微微, 罗婷婷. miR-29b-3p靶向IGF1调控非酒精性脂肪肝脂质代谢及肝纤维化[J]. 中国比较医学杂志, 2021, 31(1):66-72.
[12]	Hribal ML, Procopio T, Petta S, et al. Insulin-like growth factor-I, inflammatory proteins, and fibrosis in subjects with nonalcoholic fatty liver disease[J]. J Clin Endocr Metab, 2013, 98(2):E304-308. doi: 10.1210/jc.2012-3290 URL
[13]	邹琳, 李铁岩, 钱丽娟, 等. GH/IGF1轴对非酒精性脂肪肝病脂代谢的影响及可能机制研究[J]. 中国现代医学杂志, 2019, 29(3):15-22.
[14]	Hagström H, Stål P, Hultcrantz R, et al. IGFBP-1 and IGF-I as markers for advanced fibrosis in NAFLD-a pilot study[J]. Scand J Gastroentero, 2017, 52(12):1427-1434. doi: 10.1080/00365521.2017.1379556 pmid: 28927302
[15]	Marques V, Afonso M, Bierig N, et al. Adiponectin leptin, and IGF-1 are useful diagnostic and stratification biomarkers of NAFLD[J]. Front Med (Lausanne), 2021, 8:683250.
[16]	Yang J, Zhou W, Wu Y, et al. Circulating IGFBP-2 levels are inversely associated with the incidence of nonalcoholic fatty liver disease: A cohort study[J]. J Int Med Res, 2020, 48(8): 300060520935219.
[17]	Petäjä EM, Zhou Y, Havana M, et al. Phosphorylated IGFBP-1 as a non-invasive predictor of liver fat in NAFLD[J]. Sci Rep, 2016, 6:24740. doi: 10.1038/srep24740 pmid: 27091074
[18]	Yao K, Tarabra E, Sia D, et al. Transcriptomic profiling of a multiethnic pediatric NAFLD cohort reveals genes and pathways associated with disease[J]. Hepatol Commun, 2022, 6(7):1598-1610. doi: 10.1002/hep4.1940 pmid: 35312185
[19]	王平, 马芳玲, 母义明, 等. 2型糖尿病伴高甘油三酯血症患者血清胰岛素样生长因子结合蛋白1水平与胰岛素抵抗的相关性分析[J]. 中国糖尿病杂志, 2007, 15(3):140-141.
[20]	Pan J, Cen L, Zhou T, et al. Insulin-like growth factor binding protein 1 ameliorates lipid accumulation and inflammation in nonalcoholic fatty liver disease[J]. J Gastroen Hepatol, 2021, 36(12):3438-3447. doi: 10.1111/jgh.15627 pmid: 34273192
[21]	Fahlbusch P, Knebel B, Hörbelt T, et al. Physiological disturbance in fatty liver energy metabolism converges on IGFBP2 abundance and regulation in mice and men[J]. Int J Mol Sci, 2020, 21(11):4144. doi: 10.3390/ijms21114144 URL
[22]	Chen X, Tang Y, Chen S, et al. IGFBP-2 as a biomarker in NAFLD improves hepatic steatosis: an integrated bioinformatics and experimental study[J]. Endocr Connect. 2021, 10(10):1315-1325. doi: 10.1530/EC-21-0353 pmid: 34524971
[23]	Liu X, Chen S, Zhang L. Downregulated microRNA-130b-5p prevents lipid accumulation and insulin resistance in a murine model of nonalcoholic fatty liver disease[J]. Am J Physiol Endocrinol Metab, 2020, 319(1):e34-e42. doi: 10.1152/ajpendo.00528.2019 URL
[24]	Runchey SS, Boyko EJ, Ioannou GN, et al. Relationship between serum circulating insulin-like growth factor-1 and liver fat in the United States[J]. J Gastroen Hepatol, 2014, 29(3):589-596. pmid: 24716226
[25]	Min HK, Maruyama H, Jang BK, et al. Suppression of IGF binding protein-3 by palmitate promotes hepatic inflammatory responses[J]. Faseb J, 2016, 30(12):4071-4082. doi: 10.1096/fsb2.v30.12 URL
[26]	Ichikawa T, Nakao K, Hamasaki K, et al. Role of growth hormone, insulin-like growth factor 1 and insulin-like growth factor-binding protein 3 in development of non-alcoholic fatty liver disease[J]. Hepatol Int, 2007, 1(2):287-294. doi: 10.1007/s12072-007-9007-4 pmid: 19669352
[27]	Hjortebjerg R. IGFBP-4 and PAPP-A in normal physiology and disease[J]. Growth Horm Igf Res, 2018, 41:7-22. doi: S1096-6374(18)30047-9 pmid: 29864720
[28]	赵嘉璐, 李伟文, 蓝伟红, 等. 胰岛素样生长因子结合蛋白4在非小细胞肺癌中的表达及作用[J]. 浙江医学, 2022, 44(6):567-570.
[29]	Demori I, Balocco S, Voci A, et al. Increased insulin-like growth factor binding protein-4 expression after partial hepatectomy in the rat[J]. Am J Physiol Gastrointest Liver Physiol, 2000, 278(3):G384-389. doi: 10.1152/ajpgi.2000.278.3.G384 URL
[30]	Mazerbourg S, Callebaut I, Zapf J, et al. Up date on IGFBP-4: Regulation of IGFBP-4 levels and functions, in vitro and in vivo[J]. Growth Horm Igf Res, 2004, 14(2):71-84. pmid: 15123166
[31]	Polyzos SA, Perakakis N, Boutari C, et al. Targeted analysis of three hormonal systems identifies molecules associated with the presence and severity of NAFLD[J]. J Clin Endocr Metab, 2020, 105(3):e390-400. doi: 10.1210/clinem/dgz172 URL
[32]	Martínez-Castillo M, Rosique-Oramas D, Medina-Avila Z, et al. Differential production of insulin-like growth factor-binding proteins in liver fibrosis progression[J]. Mol Cell Biochem, 2020, 469(1-2):65-75. doi: 10.1007/s11010-020-03728-4 pmid: 32301061
[33]	Colak Y, Senates E, Ozturk O, et al. Serum concentrations of human insulin-like growth factor-1 and levels of insulin-like growth factor-binding protein-5 in patients with nonalcoholic fatty liver disease: Association with liver histology[J]. Eur J Gastroen Hepat, 2012, 24(3):255-261. doi: 10.1097/MEG.0b013e32834e8041 URL
[34]	Nguyen XX, Muhammad L, Nietert PJ, et al. IGFBP-5 promotes fibrosis via increasing its own expression and that of other pro-fibrotic mediators[J]. Front Endocrinol (Lausanne), 2018, 9:601. doi: 10.3389/fendo.2018.00601 URL
[35]	Beattie J, Allan GJ, Lochrie JD, et al. Insulin-like growth factor-binding protein-5 (IGFBP-5): A critical member of the IGF axis[J]. Biochem J, 2006, 395(1):1-19. pmid: 16526944
[36]	Su Y, Nishimoto T, Feghali-Bostwick C. IGFBP-5 promotes fibrosis independently of its translocation to the nucleus and its interaction with nucleolin and IGF[J]. PLoS One, 2015, 10(6):e0130546. doi: 10.1371/journal.pone.0130546 URL
[37]	Umemura A, Itoh Y, Itoh K, et al. Association of gankyrin protein expression with early clinical stages and insulin-like growth factor-binding protein 5 expression in human hepatocellular carcinoma[J]. Hepatology, 2008, 47(2):493-502. pmid: 18161051
[38]	陈照丽, 陈虹, 黄秉仁. 胰岛素样生长因子结合蛋白-6与肿瘤研究进展[J]. 国外医学(肿瘤学分册), 2005, 32(4):253-255.
[39]	Qiu F, Gao W, Wang B. Correlation of IGFBP-6 expression with apoptosis and migration of colorectal carcinoma cells[J]. Cancer Biomark, 2018, 21(4):893-898. doi: 10.3233/CBM-170947 pmid: 29439316
[40]	Liso A, Venuto S, Coda ARD, et al. IGFBP-6: At the crossroads of immunity, tissue repair and fibrosis[J]. Int J Mol Sci, 2022, 23(8):4358. doi: 10.3390/ijms23084358 URL
[41]	Lisowska A, 'Swięcki P, Knapp M, et al. Insulin-like growth factor-binding protein 7 (IGFBP 7) as a new biomarker in coronary heart disease[J]. Adv Med Sci, 2019, 64(1):195-201. doi: 10.1016/j.advms.2018.08.017 URL
[42]	Yan H, Li T, Wang Y, et al. Insulin-like growth factor binding protein 7 accelerates hepatic steatosis and insulin resistance in non-alcoholic fatty liver disease[J]. Clin Exp Pharmacol Physiol, 2019, 46(12):1101-1110. doi: 10.1111/cep.v46.12 URL
[43]	Liu LX, Huang S, Zhang QQ, et al. Insulin-like growth factor binding protein-7 induces activation and transdifferentiation of hepatic stellate cells in vitro[J]. World J Gastroentero, 2009, 15(26):3246-3253. doi: 10.3748/wjg.15.3246 URL

胰岛素样生长因子-1及其结合蛋白与非酒精性脂肪性肝病发生发展的研究进展

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 43

相关文章 15

编辑推荐

Metrics

本文评价

[1]	曹宇萌, 张海燕, 刘立新. 非酒精性脂肪性肝病的病理改变与血清铁蛋白和血清铁含量变化关系的meta分析[J]. 临床荟萃, 2023, 38(3): 197-207.
[2]	王馨雪, 赵丹, 柳惠未, 叶桦, 徐梦丹. 先天免疫反应与非酒精性脂肪性肝病关系的研究进展[J]. 临床荟萃, 2022, 37(9): 846-854.
[3]	文洁. 血浆致动脉粥样硬化指数与非酒精性脂肪性肝病的相关性[J]. 临床荟萃, 2022, 37(1): 35-38.
[4]	李国焕, 谢旭, 黄志霞, 张铭业, 唐云云. 非酒精性脂肪性肝病的瞬时弹性成像技术和声辐射力脉冲成像技术的定量评价[J]. 临床荟萃, 2021, 36(6): 535-539.
[5]	赵文，张思雨，路宇，赵素贤，王荣琦，南月敏. FibroTouch联合FIB-4、APRI及GPRI评估肝纤维化[J]. 临床荟萃, 2018, 33(2): 140-144.
[6]	王欣;佘亮;杨艳红;朱振龙;王政民. 脑膜瘤相关蛋白、环氧化酶2蛋白在食管鳞癌中的表达意义及相关性研究[J]. 临床荟萃, 2012, 27(12): 1032-0.
[7]	盛慧萍;成江;朱琪;杨岩. 83例慢性乙型肝炎病毒感染者临床与病理的关系[J]. 临床荟萃, 2009, 24(23): 2086-2087.
[8]	项岫秀;张慧芹;刘秀玲;刘阁玲. 吡格列酮对2型糖尿病合并非酒精性脂肪肝病患者血浆同型半胱氨酸水平的影响[J]. 临床荟萃, 2009, 24(15): 1349-1350.
[9]	陈剑峰;党瑜华;陈魁;冯青俐;田利平. 胰岛素样生长因子-1与急性冠状动脉综合征[J]. 临床荟萃, 2007, 22(17): 1223-1225.
[10]	段雪辉;杨冬华. 血管紧张素Ⅱ与肝星状细胞的研究进展[J]. 临床荟萃, 2006, 21(5): 379-381.
[11]	张贺芳;苏胜偶. 胰岛素样生长因子-1及其结合蛋白-1与糖尿病大血管并发症的关系[J]. 临床荟萃, 2005, 20(9): 539-0.
[12]	丁里玉;李春香;林玉龙;邓国兴. 中药复方抗肝纤维化研究近况[J]. 临床荟萃, 2004, 19(10): 592-594.
[13]	杨瑞平. 老年2型糖尿病患者血清胰岛素样生长因子-1与骨质疏松关系的探讨[J]. 临床荟萃, 2003, 18(10): 567-568.
[14]	谢彦华;刘春荣. 基质金属蛋白酶抑制剂与肝纤维化[J]. 临床荟萃, 2002, 17(8): 493-495.
[15]	陈银石. 丹参合用硝苯地平抗慢性乙型肝炎肝纤维化的观察[J]. 临床荟萃, 2002, 17(22): 1331-1332.